Recruiting INTERVENTIONAL NCT07203391

Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis (TRIUMPH)

TRIUMPH - Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

Sponsor: St Vincent's Hospital, Sydney

Interventions roginolisib

Updated 2 times since 2025 Last updated: Apr 22, 2026 Started: Feb 1, 2026 Primary completion: Dec 1, 2027 Completion: Dec 1, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Uveal Melanoma, Metastatic, this trial is actively recruiting participants. The trial is conducted by St Vincent's Hospital, Sydney and has accumulated 2 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Study Description(click to expand)

Based on the established activity of Tebentafusp, and the promising action of Roginolisib, this trial combines the two drugs from cycle 4 onwards in patients with metastatic uveal melanoma

Status Flow

Change History

2 versions recorded

Apr 28, 2026 — Present [daily]

Recruiting

Phase: PHASE1 → None
Nov 2025 — Apr 2026 [monthly]

Recruiting PHASE1

First recorded

Eligibility Summary

This is a combination study of Tebentafusp and the PI3Kdelta inhibitor, Roginolisib

Contact Information

Sponsor contact:

St Vincent's Hospital, Sydney

Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Melbourne, Australia
• Sydney, Australia